Vera Therapeutics, Inc.(VERA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VERA Vera Therapeutics, Inc.

Pre-Mkt 06-03 06:20:17 EDT

31.26

-2.68

-7.90%

盘前31.20

-0.06-0.19%

05:36 EDT

High35.21	Low31.03	Vol1.72M
Open34.44	D1 Closing33.94	Amplitude12.31%
Mkt Cap2.24B	Tradable Cap1.57B	Total Shares71.71M
T/O54.97M	T/O Rate3.42%	Tradable Shares50.20M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"VERA","market":"US","secType":"STK","nameCN":"Vera Therapeutics, Inc.","latestPrice":31.26,"timestamp":1780430400000,"preClose":33.94,"halted":0,"volume":1716438,"hourTrading":{"tag":"盘前","latestPrice":31.2,"preClose":31.26,"latestTime":"05:36 EDT","volume":100,"amount":3120.5,"timestamp":1780479367245,"change":-0.06,"changeRate":-0.001919,"amplitude":0.00032},"delay":0,"changeRate":-0.07896287566293449,"floatShares":50198200,"shares":71713905,"eps":-5.574565,"marketStatus":"Pre-Mkt","change":-2.68,"latestTime":"06-03 06:20:17 EDT","open":34.44,"high":35.208,"low":31.03,"amount":54971553.100140005,"amplitude":0.1231,"askPrice":32.12,"askSize":41,"bidPrice":30.02,"bidSize":30,"shortable":3,"etf":0,"ttmEps":-5.574565,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1780493400000},"marketStatusCode":1,"adr":0,"listingDate":1620964800000,"exchange":"NASDAQ","adjPreClose":31.26,"preHourTrading":{"tag":"盘前","latestPrice":31.2,"preClose":31.26,"latestTime":"05:36 EDT","volume":100,"amount":3120.5,"timestamp":1780479367245,"change":-0.06,"changeRate":-0.001919,"amplitude":0.00032},"postHourTrading":{"tag":"盘后","latestPrice":31.9,"preClose":31.26,"latestTime":"19:57 EDT","volume":16829,"amount":526621.3605,"timestamp":1780444627856,"change":0.64,"changeRate":0.020473,"amplitude":0.020473},"volumeRatio":1.7107760156643417,"impliedVol":1.1079,"impliedVolPercentile":0.86},"requestUrl":"/m/hq/s/VERA","defaultTab":"news","newsList":[{"id":"2640942997","title":"Vera Therapeutics Aligns With FDA on Earlier Atacicept Analysis to Support Potential Full Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2640942997","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640942997?lang=en_us&edition=fundamental","pubTime":"2026-06-03 00:32","pubTimestamp":1780417939,"startTime":"0","endTime":"0","summary":"Vera Therapeutics  said Tuesday it aligned with the US Food and Drug Administration on a revised analysis plan for its phase 3 Origin trial of atacicept in adults with IgA nephropathy.The biotechnology company said estimated glomerular filtration rate results from the trial are now expected in Q3. Pending those results, Vera plans to submit a supplemental biologics license application for full approval in Q4.Vera said the FDA alignment was supported by phase 2b Origin trial results showing significant reductions in proteinuria, stabilization of kidney function and a placebo-comparable safety profile, while its phase 3 Origin trial met its primary endpoint and remains ongoing to evaluate eGFR changes.Atacicept has received FDA Breakthrough Therapy Designation for IgAN, and Vera is also studying the drug in other kidney diseases, with enrollment completed in a separate dose-ranging study, the company said.Shares of Vera Therapeutics were down more than 6% in Tuesday trading.Price: 31.76,","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","LU2324357040.USD","BK4588","BK4539","LABU","VERA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640127942","title":"Vera Therapeutics announces alignment with FDA on earlier ORIGIN 3 eGFR analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2640127942","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640127942?lang=en_us&edition=fundamental","pubTime":"2026-06-03 00:27","pubTimestamp":1780417632,"startTime":"0","endTime":"0","summary":"Vera Therapeutics (VERA) announced it has aligned with the U.S. Food and Drug Administration on a revised, earlier ORIGIN 3 eGFR analysis plan to s...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vera-therapeutics-announces-alignment-with-fda-on-earlier-origin-3-egfr-analysis-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vera-therapeutics-announces-alignment-with-fda-on-earlier-origin-3-egfr-analysis-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","VERA","LU2324357040.USD","BK4588","BK4139","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640421719","title":"Raymond James sees unique buying opportunity in Vera after FDA alignment","url":"https://stock-news.laohu8.com/highlight/detail?id=2640421719","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640421719?lang=en_us&edition=fundamental","pubTime":"2026-06-03 00:26","pubTimestamp":1780417580,"startTime":"0","endTime":"0","summary":"Raymond James notes Strong Buy-rated Vera Therapeutics (VERA) announced it has alignment with FDA to carry out an earlier Phase 3 eGFR analysis to ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/raymond-james-sees-unique-buying-opportunity-in-vera-after-fda-alignment-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/raymond-james-sees-unique-buying-opportunity-in-vera-after-fda-alignment-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4539","BK4588","LU1363072403.SGD","BK4127","LABU","RJF","LU1804176565.USD","LU2324357040.USD","LU0971096721.USD","IE00B64PRP62.GBP","BK4585","VERA","LU2265009873.SGD","IE00BGHQF748.EUR","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640838945","title":"BUZZ-U.S. STOCKS ON THE MOVE-Dollar General, Vera, Amtech Systems","url":"https://stock-news.laohu8.com/highlight/detail?id=2640838945","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640838945?lang=en_us&edition=fundamental","pubTime":"2026-06-02 21:04","pubTimestamp":1780405462,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Dollar General, Vera,Amtech SystemsWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsle","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nL6N42A0NT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","LU0211326755.USD","LU0742534661.SGD","LU0784383803.USD","LU0070217475.USD","GOOX","BK4187","LU1868837300.USD","LU0345770308.USD","LU1699723380.USD","LU2077746001.SGD","SG9999018865.SGD","LU0417517546.SGD","IE00BZ1G4Q59.USD","LU0738911758.USD","LU2473716301.USD","LU2023250843.SGD","LU0957791311.USD","LU0289739343.SGD","LU2125909593.SGD","LU0072461881.USD","LU2250418816.HKD","LU2430703095.HKD","BK4170","SG9999014906.USD","LU0154236417.USD","LU2264538146.SGD","LU2360106780.USD","LU1951200564.SGD","GOOP","LU1153585028.USD","IE00B1BXHZ80.USD","LU0158827781.USD","LU0175139822.USD","HK0000914660.USD","LU2065169927.USD","LU0784385170.HKD","SG9999015952.SGD","BK4514","BK4141","LU1861215975.USD","IE00BLSP4239.USD","LU0472753341.HKD","LU0545562505.USD","LU0354030438.USD","LU1880398471.USD","BK4122","LU0061474960.USD","LU1585245621.USD","LU0310800965.SGD","HPE","SG9999017495.SGD","LU1989764748.USD","LU1267930227.SGD","LU0690374961.EUR","IE0009355771.USD","GB00B4QBRK32.GBP","LU0314104364.USD","BK4155","IE00BKDWB100.SGD","LU1316542783.SGD","LU0690374615.EUR","LU0823421333.USD","LU0149725797.USD","LU1935043536.SGD","IE00BMPRXN33.USD","BK4096","LU1989763427.SGD","LU0426417589.USD","ASYS","LU0006061336.USD","LU1989764664.SGD","SG9999014559.SGD","IE000SO60NU8.SGD","GGLL","SG9999014567.USD","BK4605","LU2746668974.SGD","LU0882574139.USD","LU1084165304.USD","IE00BLSP4452.SGD","LU1400636491.USD","LU2089985449.USD","GB00B4LPDJ14.GBP","IE00BKPKM429.USD","LU0345770993.USD","MCHP","LU0345768153.USD","LU2756315318.SGD","LU0056508442.USD","MRVU","LU1551013425.SGD","SG9999015341.SGD","LU2249611893.SGD","SARO","LU0477156953.USD","LU0477156797.USD","LU1366192091.USD","LU1861220033.SGD","LU0787776722.HKD","LU1778281490.HKD","HK0000304797.USD","LU2860962120.EUR","LU0211328371.USD","IE0004091025.USD","LU2403377893.USD","LU0158827948.USD","IE00BJLML261.HKD","LU0553294199.USD","LU2087625088.SGD","LU2381873111.SGD","LU0943347566.SGD","LU2417539215.USD","LU1261432733.SGD","HK0000304805.HKD","IE00B4R5TH58.HKD","LU0545039389.USD","LU2458330169.SGD","IE00BKVL7J92.USD","LU0321505439.SGD","LU0528227936.USD","LU2271345857.HKD","LU0061474705.USD","BK4539","LU1202635105.USD","LU2213496289.HKD","LU0557290698.USD","IE0034235295.USD","BK4147","LU1548497426.USD","LU2456880835.USD","SGXZ51526630.SGD","GOOGL","LU0070302665.USD","LU0162691827.USD","LU0426412945.USD","LU2491050071.SGD","SG9999000418.SGD","LU2102340556.USD","LU0823434740.USD","SG9999015358.SGD","LU2362541273.HKD","BK4504","MRVL","LU2097344431.USD","LU1894683348.USD","LU2065170008.USD","IE00BD6J9T35.USD","IE00B19Z9505.USD","LU2322448957.HKD","LU0109394709.USD","LU2106854487.HKD","LU0265550946.USD","IE000M9KFDE8.USD","LU0210533765.USD","LU0267386448.USD","LU0949170772.SGD","BK4612","LU1201861165.SGD","LU1894683264.USD","LU0648000940.SGD","LU0138981039.USD","GGLS","VERA","BK4550","LU2360107168.USD","LU1951198990.SGD","LU1066053197.SGD","LU1201861249.SGD","LU0203345920.USD","LU1989772923.USD","BK4527","SG9999014880.SGD","IE00B19Z3B42.SGD","LU2491049909.HKD","IE000MB6IJN5.SGD","LU2999663052.SGD","GOOW","IE00BK4W5M84.HKD","LU0127658192.USD","IE00BYXW3230.USD","LU0256863902.USD","LU0128525929.USD","LU0820561818.USD","IE00B19Z8X17.USD","IE0001KFT4U8.USD","LU1815333072.USD","LU0052756011.USD","LU0130518102.USD","LU2471134879.HKD","LU1670627923.USD","LU1169590202.USD","BK4604","LU0942090050.USD","LU0708995401.HKD","LU0310800379.SGD","LU2168563687.JPY","BK4585","LU2430703251.USD","LU0130103400.USD","MVLL","LU2404859741.USD","BK4581","IE00BFMHRM44.USD","LU0174119429.USD","LU2272731782.SGD","IE0000B7K699.USD","BK4075","BK4602","LU2362540622.SGD","LU1116320901.HKD","LU2275660780.HKD","SG9999003800.SGD","LU1196500208.SGD","LU1043141123.HKD","LU1988902786.USD","LU0784385840.USD","BK4543","HK0000819398.USD","LU2242649171.HKD","LU0215105999.USD","SG9999011175.SGD","BK4534","LU0211327993.USD","LU1032955483.USD","SGXZ99366536.SGD","BK4573","LU2168564222.USD","LU0251132253.USD","SG9999018857.SGD","BK4576","LU0276348264.USD","BK4104","LU0170899867.USD","LU1868836914.USD","LU2505996509.AUD","LU1244550494.USD","LU0689472784.USD","LU1400636657.SGD","LU2491050154.USD","BK4209","DG","FULC","LU1059921491.USD","LU2394011477.USD","BK4007","LU2092627202.USD","LU0048573561.USD","BK4533","LU0096364046.USD","LU0234572021.USD","LU0957808578.USD","BK4592","LU2089284900.SGD","LU0289961442.SGD","LU0345769631.USD","LU1720051017.SGD","LU2602419157.SGD","LU2111349929.HKD","LU2462591277.SGD","LU2065171311.SGD","LU0124676726.USD","LU0868494708.USD","IE00BDRTCR15.USD","LU0107464264.USD","LU0476273544.USD","LU1791710400.SGD","LU0316494557.USD","BK4529","LU0323591593.USD","LU1430594728.SGD","LU0069063385.USD","IE00BQXX3C00.GBP","LU0345774391.USD","LU0208291251.USD","SG9999015978.USD","LU1121112475.USD","LU1571399168.USD","LU1267930730.SGD","LU0321505868.SGD","LU0057025933.USD","LU0689626769.HKD","LU1868837136.USD","LU0345774631.USD","LU1228905540.USD","LU2191332357.HKD","LU2125154778.USD","LU2125154935.USD","LU2322448791.USD","LU0994945656.USD","LU2404859667.USD","LU1235294995.USD","LU0708994859.HKD","LU1852331112.SGD","LU0320765489.SGD","LU0345768740.USD","HK0000532082.HKD","LU0081259029.USD","LU1880398554.USD","LU0683600562.USD","LU1429558221.USD","LU1923623000.USD","IE00B19Z8W00.USD","SG9999014542.SGD","LU0792757196.USD","LU2211815571.USD","BK4574","LU0128525689.USD","LU1642822529.SGD","LU1280957306.USD","BK4503","IE00BMPRXR70.SGD","LU0353189763.USD","LU0143551892.USD","LU2247934214.USD","LU0274383776.USD","LU1119994496.HKD","BK4561","LU0225284248.USD","LU0211326839.USD","BK4532","HK0000914686.HKD","LU2054465674.USD","IE000F7OJYX1.SGD","LU0985320562.USD","GOU","LU1003077747.HKD","LU0466842654.USD","LU0080751232.USD","LU0976567544.SGD","XMTR","LU1803068623.USD","LU0980610538.SGD","LU1720051108.HKD","IE00B19Z3581.USD","LU1815336760.USD","LU1169589451.USD","LU2746668461.USD","LU2092937148.SGD","LU0889566641.SGD","LU0889565916.HKD","LU1267930813.SGD","LU0077335932.USD","LU1718418525.SGD","IE00BJT1NW94.SGD","IE00BMPRXQ63.HKD","LU1791710582.SGD","LU1496350171.SGD","LU2462591350.SGD","LU1267930490.SGD","LU0868494617.USD","LU1674673691.USD","LU1868836757.USD","LU1066051225.USD","LU1303367103.USD","LU0130517989.USD","SG9999014914.USD","LU2750360997.AUD","LU0354030511.USD","LU1323610961.USD","LU1645745479.HKD","LU2023251221.USD","LU0251142724.SGD","LU0314106906.USD","LU0320765992.SGD","BK4588","LU1823568750.SGD","LU1145028129.USD","LU0342679015.USD","IE0034235303.USD","LU2244417387.USD","LU0494093205.USD","LU0203347892.USD","LU0109391861.USD","LU1868836591.USD","LU1935042215.USD","LU0306806265.USD","LU2125909247.SGD","LU2087621335.USD","LU2326559502.SGD","LU1496350502.SGD","BK4114","LU0444973449.USD","LU0310799852.SGD","LU2028103732.USD","SG9999015986.USD","LU2265009873.SGD","IE00BQXX3D17.EUR","LU2471134952.CNY","IE00B1XK9C88.USD","LU0198837287.USD","LU0106261372.USD","BK4538","LU2065171402.SGD","LU2458330243.SGD","LU0353189680.USD","LU1992135472.HKD","BK4579","IE00BJJMRZ35.SGD","LU0096362180.USD","LU2272731600.USD","LU1244550577.SGD","LU1989763690.USD","IE00BWXC8680.SGD","IE00BK4W5L77.USD","LU1301847155.USD","SG9999001440.SGD","LU0225283273.USD","LU0048584097.USD","LU1066051498.USD","LU1914381329.SGD","LU2063271972.USD","IE0002270589.USD","IE00BSNM7G36.USD","LU0225771236.USD","LU0320765059.SGD","LU1043141396.HKD","LU1629891620.HKD","LU2360032135.SGD","IE000BZT7R73.USD","LU2168564065.EUR","LU1435385759.SGD","SGXZ31699556.SGD","LU0823421416.USD","LU2462157665.USD","LU1066051811.HKD","IE00B2B36J28.USD","LU0511384066.AUD","LU0302445910.USD","LU0964807845.USD","IE0004086264.USD","LU1221951129.SGD","LU2471134796.USD","LU2023250330.USD","LU2430703178.SGD","LU0061475181.USD","LU0312595415.SGD","GOOY","LU0985481810.HKD","LU0234570918.USD","LU0211331839.USD","LU2420271590.USD","LU1923622614.USD","LU2324357040.USD","LU1839511570.USD","LU2750360641.GBP","LU1506573853.SGD","LU2471134523.USD","LU1989772840.SGD","IE00BN8TJ469.HKD","LU2592432038.USD","LU0187121727.USD","IE00BDCRKT87.USD","BK4598","BK4512","LU0157215616.USD","LU0306807586.USD","PRAX","LPTH","LU0256863811.USD","LU0672654240.SGD","PM","LU2362541513.USD","LU0949170426.SGD","LU1046421795.USD","LU1935042488.USD","SGXZ81514606.USD","LU2236285917.USD","LU1804176565.USD","LU1670756490.USD","LU1992135399.USD","LU1366333091.USD","LU0820561909.HKD","LU2237438978.USD","LU0648001328.SGD","LU2168564495.EUR","IE0002141913.USD","SHAK","BK4157","LU0642271901.SGD","LU2954938101.SGD","LU2433249047.HKD","LU0640476718.USD","LU1674673428.USD","LU0786609619.USD","LU2023250504.SGD","IE00B7SZLL34.SGD","LU1935042991.SGD","LU1974910355.USD","IE00BBT3K403.USD","LU0444971666.USD","LU0823414478.USD","SG9999015945.SGD","LU0251131958.USD","LU2168564149.EUR","IE0034235188.USD","LU1670628061.USD","LU2272731865.HKD","LU2290526834.HKD","LU1935043023.USD","LU0265550359.USD","LU0130102774.USD","LU0289960550.SGD","LU2097829019.USD","BK4139","LU0097036916.USD","LU1551013342.USD","LU0345769128.USD","LU1878469433.USD","BK4077","LU1221951046.USD","SG9999014575.USD","LU1400636574.HKD","LU1064131342.USD","IE00BHPRN162.USD","LU0496365809.HKD","IE00BQXX3F31.USD","IE00BJTD4V19.USD","LU1232071149.USD","RZLT","LU1228905037.USD","LU0823434583.USD","LU2089283258.USD","GNRC","LU1917777945.USD","LU2357305700.SGD","LU0011850046.USD","LU1116320737.USD","LU2097344357.USD","LU0820562030.AUD","LU0784384876.USD","LU1267930573.SGD","LU1983260115.SGD","BK4515","LU2505996681.GBP","LU1633808545.USD","LU0661504455.SGD","LU2756315664.SGD","IE00BJTD4N35.SGD","LU0094547139.USD","LU1244550221.USD","LU2098885051.SGD","SG9999014898.SGD","LU2931357623.SGD","LU0029864427.USD","IE00BFTCPJ56.SGD","LU0348723411.USD","IE000WAW04H5.SGD","LU2242650005.HKD","LU0006306889.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640430529","title":"Vera Therapeutics: Buy Rating Reiterated as Atacicept’s Regulatory Path Advances; $90 Price Target Maintained","url":"https://stock-news.laohu8.com/highlight/detail?id=2640430529","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640430529?lang=en_us&edition=fundamental","pubTime":"2026-06-02 20:55","pubTimestamp":1780404948,"startTime":"0","endTime":"0","summary":"Vera Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Rami Katkhuda from LifeSci Capital maintain...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/vera-therapeutics-buy-rating-reiterated-as-atacicepts-regulatory-path-advances-90-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/vera-therapeutics-buy-rating-reiterated-as-atacicepts-regulatory-path-advances-90-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VERA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640910738","title":"Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (IDYA), Vera Therapeutics (VERA) and Regeneron (REGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640910738","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640910738?lang=en_us&edition=fundamental","pubTime":"2026-06-02 20:00","pubTimestamp":1780401656,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on IDEAYA Biosciences (IDYA), Vera Therapeutics (VERA) ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ideaya-biosciences-idya-vera-therapeutics-vera-and-regeneron-regn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ideaya-biosciences-idya-vera-therapeutics-vera-and-regeneron-regn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDYA","LU0320765992.SGD","LU0882574055.USD","LU1917777945.USD","BK4137","LU2106854487.HKD","LU0053666078.USD","REGN","LU2023250504.SGD","LU2362541513.USD","LU2324357040.USD","HCSG","LU0823434583.USD","LU2362541273.HKD","BK4139","LU2362540622.SGD","LU0128526141.USD","LU0823416689.USD","BK4539","XLV","XBI","LU0823434740.USD","LU0029874061.USD","LU0114720955.EUR","LU0109394709.USD","LU1974910355.USD","BK4585","LU2237438978.USD","BK4588","LU0289739699.SGD","LU0889565916.HKD","VERA","LABU","LU2468319806.SGD","LU2089984988.USD","BK4581","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640591059","title":"Vera Therapeutics Advances Atacicept Approval Path in IgA Nephropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2640591059","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640591059?lang=en_us&edition=fundamental","pubTime":"2026-06-02 19:37","pubTimestamp":1780400231,"startTime":"0","endTime":"0","summary":"The latest update is out from Vera Therapeutics ( ($VERA) ). On June 2, 2026, Vera Therapeutics, Inc. announced it had reached agreement with the U...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vera-therapeutics-advances-atacicept-approval-path-in-iga-nephropathy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vera-therapeutics-advances-atacicept-approval-path-in-iga-nephropathy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LU2324357040.USD","BK4588","BK4539","VERA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640815910","title":"BUZZ-Vera rises as FDA agrees to review late-stage kidney drug data for full approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2640815910","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640815910?lang=en_us&edition=fundamental","pubTime":"2026-06-02 19:36","pubTimestamp":1780400167,"startTime":"0","endTime":"0","summary":"BUZZ-Vera rises as FDA agrees to review late-stage kidney drug data for full approval** Shares of Vera Therapeutics VERA.O rise 2.9% to $34.92 premarket ** VERA says it has aligned with the U.S. Food and Drug Administration to speed up plans that could lead to full approval of its experimental kidney disease drug, atacicept** Says the FDA has agreed to review key data from a late-stage study earlier than planned, with results now expected in Q3 2026, instead of 2027** Vera plans to apply for supplemental application in Q4 based on additional trial data** Atacicept is already under review by the FDA for accelerated approval in patients with IgA Nephropathy, with a decision expected on July 7** IgA nephropathy is an autoimmune condition that can lead to kidney failure** Up to last close, stock down about 33% YTD   ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nL4N42A0YC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VERA","BK4588","LU2324357040.USD","BK4139","BK4585","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640878917","title":"Vera Therapeutics pulls forward ORIGIN phase 3 eGFR analysis of atacicept in IgA nephropathy to Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640878917","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640878917?lang=en_us&edition=fundamental","pubTime":"2026-06-02 19:03","pubTimestamp":1780398238,"startTime":"0","endTime":"0","summary":"Vera Therapeutics aligned with the FDA to pull forward a key Phase 3 kidney-function analysis for atacicept in IgA nephropathy to Q3 2026.Results will be presented in the future; the earlier readout is intended to support a path to full approval if outcomes are positive.Prior ORIGIN Phase 3 interim results were already presented, showing the trial met its primary goal with a clinically meaningful improvement versus placebo.Pending the Q3 2026 readout, a supplemental BLA is planned for Q4 2026, targeting potential full approval in 2027.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL6954DM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BKPKM429.USD","IE00BN0W2T93.GBP","VERA","IE00B3QW5Z07.USD","LU0314104364.USD","LU2095319765.USD","SG9999014039.USD","IE00B64PRP62.GBP","BK4139","BK4539","BK4112","SG9999014005.SGD","IE00BGHQF748.EUR","LU2210149790.SGD","IE00BN0W2V16.EUR","NDAQ","IE00BN0W2W23.USD","LU2210150020.SGD","SG9999014021.USD","BK4585","LU2324357040.USD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640912786","title":"Vera Therapeutics, - Revised Origin 3 Egfr Analysis Planned for Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640912786","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640912786?lang=en_us&edition=fundamental","pubTime":"2026-06-02 19:00","pubTimestamp":1780398001,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nTUABB3HJY:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LU2324357040.USD","BK4539","BK4585","BK4588","VERA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640912735","title":"Vera Therapeutics Announces Alignment With U.S. FDA on Earlier Origin Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults With Iga Nephropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2640912735","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640912735?lang=en_us&edition=fundamental","pubTime":"2026-06-02 19:00","pubTimestamp":1780398001,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nTUABB3HJY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","LU2324357040.USD","BK4585","VERA","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640891275","title":"Vera Therapeutics, - Pdufa Date Set for July 7, 2026 for Atacicept in Igan","url":"https://stock-news.laohu8.com/highlight/detail?id=2640891275","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640891275?lang=en_us&edition=fundamental","pubTime":"2026-06-02 19:00","pubTimestamp":1780398001,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nTUABB3HJY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2324357040.USD","BK4585","BK4539","VERA","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640738912","title":"Vera Therapeutics, - Plans to Submit Sbla in Q4 2026 for Potential Full Approval in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2640738912","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640738912?lang=en_us&edition=fundamental","pubTime":"2026-06-02 19:00","pubTimestamp":1780398001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nTUABB3HJY:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","VERA","LU2324357040.USD","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638528739","title":"Vera Therapeutics shareholders elect Class II directors at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2638528739","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638528739?lang=en_us&edition=fundamental","pubTime":"2026-05-27 04:55","pubTimestamp":1779828918,"startTime":"0","endTime":"0","summary":"Vera Therapeutics held its annual shareholder meeting on May 21, 2026.Shareholders selected three Class II directors to serve through the 2029 annual meeting.Shareholders backed a non-binding advisory resolution on executive pay.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 26, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDL50ZySY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4539","BK4585","LU2324357040.USD","VERA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637632299","title":"Analysts’ Top Healthcare Picks: Concentra Group Holdings Parent, Inc. (CON), Vera Therapeutics (VERA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2637632299","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637632299?lang=en_us&edition=fundamental","pubTime":"2026-05-23 20:20","pubTimestamp":1779538831,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Concentra Group Holdings Parent, Inc. (CON) and Vera...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-concentra-group-holdings-parent-inc-con-vera-therapeutics-vera-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-concentra-group-holdings-parent-inc-con-vera-therapeutics-vera-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2324357040.USD","BK4581","XLV","BK4185","LU0128526141.USD","BK4139","BK4588","LU0029874061.USD","BK4585","BK4137","XBI","LABU","HCSG","CON","VERA","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637731627","title":"Analysts Are Bullish on These Healthcare Stocks: Inovio Pharmaceuticals (INO), Vera Therapeutics (VERA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2637731627","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637731627?lang=en_us&edition=fundamental","pubTime":"2026-05-22 19:20","pubTimestamp":1779448856,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Inovio Pharmaceuticals (INO), Vera Therapeutics (VER...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-inovio-pharmaceuticals-ino-vera-therapeutics-vera-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-inovio-pharmaceuticals-ino-vera-therapeutics-vera-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","INO","BK4588","LU2324357040.USD","BK4568","BK4583","BK4539","BK4585","VERA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637535453","title":"Vera Therapeutics (VERA) Is Down 11.6% After Wider Q1 Loss Highlights Rising Cost Burden","url":"https://stock-news.laohu8.com/highlight/detail?id=2637535453","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637535453?lang=en_us&edition=fundamental","pubTime":"2026-05-22 03:27","pubTimestamp":1779391667,"startTime":"0","endTime":"0","summary":"Vera Therapeutics, Inc. reported first-quarter 2026 results, posting a net loss of US$121.03 million, compared with US$51.69 million a year earlier, and a basic loss per share from continuing operations of US$1.69 versus US$0.81.\nThe sharp year-on-year increase in both total net loss and loss per share highlights rising costs or investments that are weighing more heavily on the company’s income statement.\nNext, we’ll examine how this widening net loss shapes Vera Therapeutics’ investment...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vera/vera-therapeutics/news/vera-therapeutics-vera-is-down-116-after-wider-q1-loss-highl","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vera/vera-therapeutics/news/vera-therapeutics-vera-is-down-116-after-wider-q1-loss-highl","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","LU2324357040.USD","BK4539","BK4585","VERA","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635031415","title":"Vera Therapeutics Is Maintained at Outperform by Evercore ISI Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2635031415","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635031415?lang=en_us&edition=fundamental","pubTime":"2026-05-16 01:49","pubTimestamp":1778867340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VERA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 15, 2026 13:49 ET (17:49 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VERA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635826110","title":"Vera Therapeutics (VERA) Receives a Buy from Evercore ISI","url":"https://stock-news.laohu8.com/highlight/detail?id=2635826110","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635826110?lang=en_us&edition=fundamental","pubTime":"2026-05-15 20:37","pubTimestamp":1778848635,"startTime":"0","endTime":"0","summary":"In a report released today, Gavin Clark-Gartner from Evercore ISI maintained a Buy rating on Vera Therapeutics, with a price target of $91.00. Clar...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/vera-therapeutics-vera-receives-a-buy-from-evercore-isi-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/vera-therapeutics-vera-receives-a-buy-from-evercore-isi-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4539","BK4139","LU2324357040.USD","BK4588","VERA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635530917","title":"Vera Therapeutics CEO Marshall Fordyce disposes 18,500 shares for $834,058","url":"https://stock-news.laohu8.com/highlight/detail?id=2635530917","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635530917?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:27","pubTimestamp":1778704065,"startTime":"0","endTime":"0","summary":"Vera Therapeutics President and CEO Marshall Fordyce sold 18,500 Class A common shares on May 12, 2026.Sales priced at weighted-average USD 36.64 per share for 14,219 shares, weighted-average USD 37.09 per share for 4,281 shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 13, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL6h5y1M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Vera Therapeutics CEO Marshall Fordyce disposes 18,500 shares for $834,058","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","VERA","BK4585","BK4539","LU2324357040.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.veratx.com","stockEarnings":[{"period":"1week","weight":-0.0897},{"period":"1month","weight":-0.1119},{"period":"3month","weight":-0.2116},{"period":"6month","weight":-0.2664},{"period":"1year","weight":-0.0151},{"period":"ytd","weight":-0.3827}],"compareEarnings":[{"period":"1week","weight":0.012},{"period":"1month","weight":0.054},{"period":"3month","weight":0.1087},{"period":"6month","weight":0.1098},{"period":"1year","weight":0.2815},{"period":"ytd","weight":0.1139}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":0.057587},{"month":2,"riseRate":0.4,"avgChangeRate":0.015839},{"month":3,"riseRate":0.4,"avgChangeRate":-0.047765},{"month":4,"riseRate":0,"avgChangeRate":-0.103447},{"month":5,"riseRate":0.2,"avgChangeRate":-0.049498},{"month":6,"riseRate":0.333333,"avgChangeRate":0.117098},{"month":7,"riseRate":0.8,"avgChangeRate":0.137629},{"month":8,"riseRate":0.6,"avgChangeRate":0.019112},{"month":9,"riseRate":0.6,"avgChangeRate":0.088867},{"month":10,"riseRate":0.2,"avgChangeRate":-0.071412},{"month":11,"riseRate":0.8,"avgChangeRate":0.292871},{"month":12,"riseRate":0.6,"avgChangeRate":0.07812}],"exchange":"NASDAQ","name":"Vera Therapeutics, Inc.","nameEN":"Vera Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Vera Therapeutics, Inc.(VERA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Vera Therapeutics, Inc.(VERA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Vera Therapeutics, Inc.,VERA,Vera Therapeutics, Inc.股票,Vera Therapeutics, Inc.股票老虎,Vera Therapeutics, Inc.股票老虎国际,Vera Therapeutics, Inc.行情,Vera Therapeutics, Inc.股票行情,Vera Therapeutics, Inc.股价,Vera Therapeutics, Inc.股市,Vera Therapeutics, Inc.股票价格,Vera Therapeutics, Inc.股票交易,Vera Therapeutics, Inc.股票购买,Vera Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Vera Therapeutics, Inc.(VERA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Vera Therapeutics, Inc.(VERA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}